Bellerophon Therapeutics, Inc. financial data

Symbol
BLPH on OTC
Industry
Pharmaceutical Preparations
Location
184 Liberty Corner Road, Suite 302, Warren, NJ
State of incorporation
DE
Fiscal year end
December 31
Former names
Bellerophon Therapeutics LLC (to 2/13/2015)
Latest financial report
10-Q - Q3 2023 - Nov 14, 2023

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 265 % -50.4%
Debt-to-equity 78.5 % +110%
Return On Equity -165 % -24%
Return On Assets -92.2 % +4.6%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 12.2M shares +28.2%
Common Stock, Shares, Outstanding 12.2M shares +28.2%
Entity Public Float 8.8M USD -75.7%
Common Stock, Value, Issued 122K USD +28.4%
Weighted Average Number of Shares Outstanding, Basic 12.2M shares +28.2%
Weighted Average Number of Shares Outstanding, Diluted 12.2M shares +28.2%

Income Statement

Label TTM Value / Value Unit Change %
General and Administrative Expense 6.97M USD +20.9%
Operating Income (Loss) -11M USD +48.8%
Nonoperating Income (Expense) 109K USD +132%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -10.5M USD +51%
Income Tax Expense (Benefit) -1.28M USD
Net Income (Loss) Attributable to Parent -9.25M USD +51.5%
Earnings Per Share, Basic -0.84 USD/shares +57.8%
Earnings Per Share, Diluted -0.84 USD/shares +57.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 4.38M USD -61.3%
Assets, Current 4.98M USD -58.7%
Property, Plant and Equipment, Net 2K USD -97%
Operating Lease, Right-of-Use Asset 0 USD -100%
Other Assets, Noncurrent 0 USD -100%
Assets 4.98M USD -60.5%
Liabilities, Current 1.26M USD -75.7%
Operating Lease, Liability, Noncurrent 8K USD -99%
Liabilities 1.26M USD -75.8%
Retained Earnings (Accumulated Deficit) -256M USD -3.75%
Stockholders' Equity Attributable to Parent 3.72M USD -49.9%
Liabilities and Equity 4.98M USD -60.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities 3.27M USD
Net Cash Provided by (Used in) Financing Activities 4.98M USD
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 12.2M shares +28.2%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 8.25M USD
Deferred Tax Assets, Valuation Allowance 56.6M USD +8.53%
Deferred Tax Assets, Gross 56.6M USD +8.53%
Operating Lease, Liability 0 USD -100%
Lessee, Operating Lease, Liability, to be Paid 205K USD -79.3%
Property, Plant and Equipment, Gross 2.53M USD 0%
Operating Lease, Liability, Current 8K USD -99%
Lessee, Operating Lease, Liability, to be Paid, Year Two 205K USD -73.8%
Lessee, Operating Lease, Liability, to be Paid, Year One 205K USD -73.8%
Operating Lease, Weighted Average Discount Rate, Percent 0.05 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 2K USD -93.8%
Deferred Tax Assets, Operating Loss Carryforwards 41.2M USD +1.48%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Operating Lease, Payments 599K USD -22.8%
Additional Paid in Capital 260M USD +2.17%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 580K USD -19.9%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%